Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surg Pathol Clin 2016 Mar;9(1):101-16
Date
03/05/2016Pubmed ID
26940271DOI
10.1016/j.path.2015.09.009Scopus ID
2-s2.0-84959212384 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
This article provides an overview of the role of flow cytometry in the diagnosis and follow-up of plasma cell myeloma. A brief introduction to the general immunophenotypic features of normal and myeloma plasma cells is provided, followed by a discussion of technical issues as they relate to the application of flow cytometry in this entity. The prognostic and therapeutic utility of flow cytometric immunophenotyping in myeloma is also analyzed, with an emphasis on the growing role of minimal residual analysis as potential biomarker for evaluating treatment efficacy and for tailoring risk-adapted treatment, in prospective clinical trials.
Author List
Olteanu HMESH terms used to index this publication - Major topics in bold
Diagnosis, DifferentialFlow Cytometry
Humans
Immunophenotyping
Immunotherapy
Multiple Myeloma
Neoplasm, Residual
Prognosis